Home LiteratureArticle Details
PMID: 273926 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII).

Griffin JH

Abstract

The mechanism by which negatively charged substances such as celite, kaolin, or ellagic acid contribute to the surface-dependent activation of Hageman factor (Factor XII) was studied. Kinetic studies of the proteolytic activation of (125)I-labeled human Hageman factor by human plasma kallikrein, plasma, activated Factor XI, and trypsin were performed in the presence and absence of high molecular weight kininogen and surface materials such as celite, kaolin, or ellagic acid. The results showed that surface-bound Hageman factor was 500 times more susceptible than soluble Hageman factor to proteolytic activation by kallikrein in the presence of high molecular weight kininogen. Surface binding of Hageman factor enhanced its cleavage by plasmin, activated Factor XI, and trypsin by 100-fold, 30-fold, and 5-fold, respectively. On a molar basis, trypsin was twice as potent as kallikrein in the cleavage of the surface-bound Hageman factor, while plasmin and activated Factor XI were an order of magnitude less potent than kallikrein. Kallikrein even at concentrations as low as 0.5 nM (i.e., 1/1000th of the concentration of prekallikrein in plasma) was very potent in the limited proteolysis of the surface-bound Hageman factor. These results suggest that substances classically known as "activating surfaces" promote the activation of Hageman factor indirectly by altering its structure such that it is much more susceptible to proteolytic activation by other plasma or cellular proteases.

MeSH Terms
Adsorption Anions Ellagic Acid Factor XI/metabolism Factor XII/metabolism Kallikreins/metabolism Kaolin Kininogens/metabolism Molecular Weight Peptide Fragments/metabolism Surface Properties Trypsin/metabolism
Chemicals
Anions Kininogens Peptide Fragments Ellagic Acid Kaolin Factor XII Factor XI Kallikreins Trypsin
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Griffin J H
References (33)
33 references, click to expand
  1. Deficiency of factor XII-dependent plasminogen proactivator in prekallikrein-deficient plasma.
    J Lab Clin Med. 1978 Jan;91(1):148-55 PMID: 73563
  2. Flaujeac trait. Deficiency of human plasma kininogen.
    J Clin Invest. 1975 Dec;56(6):1663-72 PMID: 127805
  3. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
    Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683-7 PMID: 266208
  4. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.
    Proc Natl Acad Sci U S A. 1977 Oct;74(10):4636-40 PMID: 270705
  5. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.
    J Exp Med. 1978 Mar 1;147(3):719-29 PMID: 632748
  6. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
    J Clin Invest. 1977 Jun;59(6):1167-75 PMID: 864009
  7. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.
    J Clin Invest. 1977 Jul;60(1):18-31 PMID: 874082
  8. Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII.
    J Biol Chem. 1977 Sep 25;252(18):6432-7 PMID: 893417
  9. Characterization of bovine factor XIIa (activated Hageman factor).
    Biochemistry. 1977 Sep 20;16(19):4182-8 PMID: 901768
  10. Mechanism of activation of bovine factor VII. Products of cleavage by factor Xa.
    J Biol Chem. 1976 Aug 25;251(16):4749-802 PMID: 956165
  11. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor.
    Proc Natl Acad Sci U S A. 1976 Aug;73(8):2554-8 PMID: 1066663
  12. Partial purification and characterization of contact activation cofactor.
    J Clin Invest. 1975 Nov;56(5):1082-92 PMID: 1184736
  13. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.
    J Clin Invest. 1975 Dec;56(6):1650-62 PMID: 1202089
  14. Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis.
    J Lab Clin Med. 1976 Feb;87(2):327-37 PMID: 1245795
  15. Origin of the high molecular weight activator of prekallikrein.
    J Biol Chem. 1973 Nov 25;248(22):7742-7 PMID: 4127217
  16. A method of trace iodination of proteins for immunologic studies.
    Int Arch Allergy Appl Immunol. 1966;29(2):185-9 PMID: 4160044
  17. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.
    J Exp Med. 1971 Apr 1;133(4):696-712 PMID: 4251126
  18. The kinin system of human plasma. VI. The action of plasmin.
    Proc Soc Exp Biol Med. 1971 Dec;138(3):959-66 PMID: 4257083
  19. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein.
    J Exp Med. 1973 Dec 1;138(6):1564-83 PMID: 4271629
  20. The spectrum of cobalt bovine procarboxypeptidase A, an index of catalytic function.
    Proc Natl Acad Sci U S A. 1972 Sep;69(9):2442-5 PMID: 4506766
  21. Measurement of fibrinopeptide A in human blood.
    J Clin Invest. 1974 Jul;54(1):43-53 PMID: 4600045
  22. The relation of the -amino group of trypsin to enzyme function and zymogen activation.
    Biochemistry. 1973 Jan 30;12(3):420-6 PMID: 4683488
  23. Prekallikrein deficiency in man.
    J Exp Med. 1973 Dec 1;138(6):1345-55 PMID: 4762550
  24. Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma.
    Circ Res. 1974 May;34(5):641-51 PMID: 4826936
  25. The autoactivation of trypsinogen.
    J Biol Chem. 1971 Nov;246(21):6661-5 PMID: 5167250
  26. The biology and pathology of the initial stages of blood coagulation.
    Prog Hematol. 1966;5:204-45 PMID: 5337570
  27. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties.
    Blood. 1965 Nov;26(5):521-32 PMID: 5845778
  28. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor.
    Proc Soc Exp Biol Med. 1953 Jan;82(1):171-4 PMID: 13037836
  29. Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation.
    J Physiol. 1958 Nov 10;144(1):1-22 PMID: 13599105
  30. The interrelationship of coagulation of plasma and release of peptides.
    Ann N Y Acad Sci. 1963 Feb 4;104:133-45 PMID: 13933028
  31. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma.
    J Clin Invest. 1955 Apr;34(4):602-13 PMID: 14367514
  32. [Role of the contact factor (Hageman factor) in fibrinolysis].
    Thromb Diath Haemorrh. 1959 Sep 1;3:593-603 PMID: 14427142
  33. Fitzgerald Trait: Deficiency of a Hitherto Unrecognized Agent, Fitzgerald Factor, Participating in Surface-Mediated Reactions of Clotting, Fibrinolysis, Generation of Kinins, and the Property of Diluted Plasma Enhancing Vascular Permeability (PF/Dil).
    J Clin Invest. 1975 May;55(5):1082-9 PMID: 16695963
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
1978-04-00
Pages
1998-2002
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC392470
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]